SARS-CoV NSP8 Antibody

Western Blot: SARS-CoV NSP8 Antibody [NBP2-89180] - immunoprecipitation followed by western blotting using Anti-nsp8 shows a predominant band at 21.8 kDa corresponding to full length SARS protein (panel A). Immunofluorescence Microscopy using anti-nsp8 6-h post infection of Vero-E6 cells (Panel B). For detection Cy3 conjugated Goat-anti-Rabbit IgG was used.

Immunocytochemistry/Immunofluorescence: SARS-CoV NSP8 Antibody [NBP2-89180] - Microscopy using anti-nsp8 6-h post infection of Vero-E6 cells (Panel B). For detection Cy3 conjugated Goat-anti-Rabbit IgG was used.

Product Discontinued

SARS-CoV NSP8 Antibody Summary

• Description: Store vial at -20C prior to opening. Aliquot contents and freeze at -20C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4C as an undiluted liquid. Dilute only prior to immediate use.
• Immunogen: This whole rabbit serum was produced by repeated immunizations with a purified His- tagged recombinant protein corresponding to full-length SARS-Coronavirus nsp8.
• Specificity: This antibody is directed against SARS-Coronavirus nsp8 protein. The product is neat antiserum. Cross reactivity with homologues from other sources has not been determined.
• Predicted Species: SARS-CoV-2 (97%). Backed by our 100% Guarantee.
• Isotype: Serum
• Clonality: Polyclonal
• Host: Rabbit
• Purity: Sterile filtered

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:300
  • Western Blot 1:1000
• Application Notes: This antibody has been tested for use in immunofluorescence microscopy, immunoelectron microscopy, immunoprecipitation and by western blot. Specific conditions for reactivity should be optimized by the end user. Expect a band of approximately 22 kDa in size corresponding to SARS-CoV nsp8 by western blotting in the appropriate cell lysate or extract. For immunofluorescence microscopy, Vero-E6 cells, grown on glass slides, were infected with SARS-CoV-Fr1 strain for 1 h at 37 degrees C. Infection occurred in PBS/DEAE/2% FCS followed by exchange to EMEM/25mM HEPES/2% FCS. Cells were fixed with PBS/3% PFA. After washing fixed cells, antibody incubation was performed in PBS/5% FCS for 30 min.

Reactivity Notes

Immunogen displays the following percentage of sequence identity for non-tested species: COVID-19 (97%)

Packaging, Storage & Formulations

• Storage: Store at -20C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles.
• Buffer: Antiserum
• Preservative: 0.01% Sodium Azide
• Purity: Sterile filtered

Alternate Names for SARS-CoV NSP8 Antibody

• COVID-19
• NSP8

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for SARS-CoV NSP8 Antibody (NBP2-89180)(4)

Publications using NBP2-89180

• Radovic S, Meng W, Chen L et al. SARS-CoV-2 infection of kidney tissues from severe COVID-19 patients Journal of medical virology 2023-02-01 [PMID: 36756942] (IHC)
• Wei L, Sun Y, Guo J Genome-wide CRISPR screens identify noncanonical translation factor eIF2A as an enhancer of SARS-CoV-2 programmed -1 ribosomal frameshifting bioRxiv 2023-01-25
• Meng W, Guo S, Cao S et al. Development and characterization of a new monoclonal antibody against SARS-CoV-2 NSP12 (RdRp) Journal of medical virology 2022-10-21 [PMID: 36271490]
• Sun Y, Abriola L, Niederer RO et al. Restriction of SARS-CoV-2 replication by targeting programmed -1 ribosomal frameshifting Proceedings of the National Academy of Sciences of the United States of America 2021-06-29 [PMID: 34185680] (WB)